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Introduction
Breast cancer is a heterogeneous disease but can be grouped into major subtypes by both traditional histopathological features (e.g. histological type, grade, ER, PR and HER2 status) used in diagnostic practice as well as the newer microarray-based molecular profiling [1, 2] .
The new molecular taxonomy describes 5 major subtypes (Luminal-A, Luminal-B, Basal-like, HER2 and Normal) that overlap with different clinico-pathological classification systems, correlate with clinical behavior and are vital for informing patient management.
Early breast cancers (stage I, II, IIIA and operable stage IIIC) are treated with curative intent using surgery followed by radiotherapy. To avoid recurrence from micrometastases, adjuvant treatments (hormonal agents, trastuzumab and cytotoxic chemotherapy in sequence and/or in combination) are often prescribed. The administration of systemic therapies is driven by assessment of clinico-pathologic features such as tumor size, nodal involvement, hormone receptor status, and Her2 gene amplification [3] [4] [5] . Stage IIIB and inoperable stage IIIC breast cancer are treated with systemic chemotherapy or hormone therapy, in the neoadjuvant settings, to downstage locally advanced tumors followed by surgery and radiotherapy [6] .
Stage IV or metastatic breast cancer is treated with palliative intent using hormonal agents, trastuzumab or lapatinib, conventional cytotoxic drugs. These drugs tend to be employed in sequence often as single agents, although some of these agents may be used in two-drug combinations.
While adjuvant therapy plays a crucial part in the management of early breast cancer, local relapse still occurs. A meta-analysis of 42,000 women in 78 clinical trials demonstrates that the 10-year local recurrence rate in patients who received lumpectomy and radiation was 13% compared to 47% for patients who did not receive radiation. In the case of patients receiving a mastectomy and radiation, the recurrence rate was 8% compared to 28% for those not receiving radiation [7] . Despite the reduction of recurrence by the use of radiotherapy, the 15-years overall survival of these patients is marginally affected and mortality rates are 26% and 48% following breast lumpectomy and radiotherapy for lymph node negative and positive breast disease, respectively. Even higher mortality rates of 31% and 55% are reported for patients receiving a mastectomy and radiation for lymph node negative and positive disease, respectively [7] . At present around 40% of all breast cancer patients suffer a recurrence; 10-20% of all recurrences are local and 60% to 70% are distant metastases [8] .
While several prognostic factors, depending on breast cancer type, can predict recurrence, the explanations for recurrences remain hypothetical. Under-treatment of breast cancer patients with adjuvant therapies due to borderline classification of the disease may contribute to some but not all recurrences. Local and metastatic recurrence after surgical treatment of the primary tumor may be due to local deposits of cancer cells that were not removed during surgery or early micrometastases that were resistant to adjuvant treatments. Recurrence and disease spread in locally advanced breast cancer may be explained by resistance to neoadjuvant systemic therapy and/or radiotherapy. Conventional therapeutic approaches (chemotherapy and radiotherapy) as well as most of current targeted therapies are based on an intention to target all cells similarly using maximum tolerated doses. Nevertheless, the relative failure of these therapies to cure most solid cancers as well as local and metastatic disease recurrence has revived interest in the controversial cancer stem cell (CSC) model as it described a therapy-resistant subpopulation of cells that are capable of tumor "regeneration".
The existence of a radiation-resistant subpopulations of tumor cells has been long proposed by radiobiologists [9, 10] , but whether these cells can be prospectively identified and targeted is an ongoing debate. A similar difficulty applies to the CSC hypothesis, which defines "a small subset of cells within a cancer that constitutes a reservoir of self-sustaining cells with the exclusive ability to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor" [11] . Preclinical data from cell lines and tumor models support the concept that breast cancer-derived tumor-initiating cells are relatively resistant to radiation and chemotherapy. The relationship between the CSC hypothesis and the normal breast epithelial hierarchy has fueled much speculation on breast cancer histogenesis i.e. the normal cellular origins of specific breast cancer subtypes. How important understanding tumor cell origin will be in improving breast cancer outcomes is debatable. Therefore, we believe that studies concentrating on the treatment-resistant cells among the heterogeneous cell populations of human breast cancer could be helpful in not only identifying patients requiring more aggressive treatment and monitoring but also in broadening the scope for identification of new therapeutic targets and approaches. Clear parallels can be drawn between these studies and the investigations of putative breast cancer stem cells. Is there sufficient preclinical and clinical evidence, however, for uniting the concepts of treatment-resistant cells and breast cancer stem-like cells? Here, we will review data for each concept with a focus on discussing new and improved methods of reducing breast cancer recurrence after therapy, particularly after radiotherapy by targeting the mechanisms of resistance.
Cancer models
Two models have been proposed to account for solid tumor heterogeneity: the "clonal evolution" and the "cancer stem cell" models [12] . The conventional clonal evolution model is a non-hierarchical model that proposes all cells within a tumor have an equal chance of acquiring the genetic mutations necessary for driving tumor growth. In this model, cancer cells over time stochastically acquire a myriad of combinations of mutations over time in a by-chance fashion, so that by natural under selection pressures, the most aggressive cells drive the most aggressive cells drive tumor propagation progression and therapy resistance.
The cancer stem cell model is a hierarchical model proposing that only a subset of cells can propagate the tumor by acting as multipotent progenitors, with the ability to recapitulate the molecular and phenotypic heterogeneity of the original tumor, mimicking stem cells. The genetic basis for heterogeneity needs to be addressed in both of these cancer models (see section 3.5), however it is important to emphasize that CSCs are not necessarily the product of normal stem cell transformation; they may arise from restricted progenitor or differentiated cells by acquiring stem cell-like properties [11, 13, 14 
Breast cancer subtypes, BCSCs and the normal cell of origin
The identification of distinct intrinsic subtypes of breast cancer begs the question as to whether the different subtypes contain different CSC phenotypes as well as the cell of origin from which each subtype arises [13].
Different cancer subtypes; different BCSCs?
A study of 321 node-negative and 318 node-positive breast cancers concluded that identification of putative CSCs in situ identified high-risk breast cancer patients [54] . that CSCs specific for luminal type A and type B breast cancers are yet to be reported.
Cell of origin and breast cancer histogenesis
The cancer stem cell hypothesis does not necessarily imply origin from adult stem cells although self-renewal and multilineage potential are cardinal features of both. Better understanding of the differentiation hierarchy of normal breast tissue may yield insights into understanding histogenesis, hierarchical organization, and heterogeneity of breast tumors.
However, caution must be exercised in over-interpreting similarities in these features to mean they indicate similarities in cell of origin between normal and malignant breast tissue. 
Criticisms of the CSC hypothesis
The CSC model is not universally accepted and some of the properties of CSCs can be explained by the clonal evolution model [51, [65] [66] [67] . One of the main criticisms is the use of xenotransplantations where the microenvironment in mice is not suited to supporting the growth of tumors from human cancer cells, which would otherwise be tumorigenic. However, this criticism has been addressed using a syngeneic p53-null mouse mammary tumor model, which provided direct evidence for the existence of a tumor-initiating subpopulation of CSCs
Another criticism is an assumption that CSCs express a stable phenotype in a disease marked 
Not this CSC, the other one: Clonal evolution of BCSCs?
Despite the pessimistic discussion of the CSC hypothesis, positive identification of the most primitive normal or malignant stem cells remains the key challenge in the field. In normal breast tissue from women and mice, it appears that primitive normal stem cells with bi/multipotent potential can be identified [17] [18] [19] . (Figure 2 ). Such a model may account for the heterogeneity within the distinct subtypes of breast cancer as well as the genetic divergence within a tumor and among the metastases, which arise from CSCs within the primary tumor but which accumulate additional mutations in their new environment.
While we seek to understand different models of breast cancer initiation and progression (CSC, clonal evolution, or mixed), disease recurrence and spread from cancer cells that resist therapeutic intervention remains a clinical reality. The remainder of this review addresses the implications of resistant "CSCs" and "clones" for breast cancer therapy and the possible therapeutic strategies that may be used to enhance patient outcomes.
Implication of CSC on breast cancer therapy
Cytotoxic drugs principally target rapidly dividing cells, thus a self-renewing, long-lived and relatively quiescent CSC population may be more resistant to therapy. Practically, the definition of CSCs implies that recurrence after anticancer treatments is associated with the survival of these cells. This concept has gained much prominence in the field of cancer research with several studies reporting the enrichment of CSCs after conventional treatments possible to summarize all aspects of the DDR pathways here; instead, we will summarize findings relating to the DDR pathways and radiation resistance of BCSCs.
BCSCs, DDR pathways and radiation resistance as an example
Pre-clinically, putative BCSCs populations were found to be radioresistant compared to tumor cells with a non-stem cell-like phenotype [80, 81] . Future studies will have to investigate these differences more closely. In vitro studies are providing mechanistic insights to radioresistance of cancer stem cells. DSBs identified by staining of γ-H2AX and ROS levels were lower in clonogenicity, and decreased apoptosis [101] . The extended G 2 phase may be used by these cells as a mechanism to prolong repair of DNA damage. These observations suggest that drugs targeting G 2 checkpoint proteins should be assessed because removing the G 2 block could make these cells more sensitive to apoptosis-inducing treatment.
Signaling in BCSCs: therapeutic opportunity
Notwithstanding the controversy surrounding phenotypic identity of BCSCs, the finding of a distinct subpopulation of breast cancer cells that contribute to chemo-and radio-resistance and organ-specific metastasis helps to set a direction for future therapeutic research [102] . Nonetheless, and to our knowledge, the effect of molecular inhibitors of the DDR and checkpoints on CSCs specifically, at least in breast cancer, has not been investigated.
Old drugs, new tricks?
Most, if not all, of the drugs discussed above, including those that directly target progeny, then this subpopulation will ultimately limit the success of the therapy. In this sense, assaulting the treatment-responsive and differentiated cancer cell clones risks clonal selection of the most resistant and aggressive CSCs, which are left behind in the tumor mass as a "Trojan Horse". In the final analysis, the most effective and rational approach may be first to "de-bulk" the tumor mass with conventional agents before specifically targeting this therapylimiting CSC population with newer and yet-to-be discovered agents. ) with anti-CSC activity or chemo-and/or radio-sensitizing activity to increase the probability of killing these rare treatment-resistant populations after first removing the bulk of non-CSCs.
Concluding remarks
While the question of cell of origin and histogenesis is biologically relevant, CSCs as a treatment-resistant subpopulation of tumor cells is of greater therapeutic relevance. Additional prospective clinical investigations to evaluate CSC phenotypes using different markers and/or gene expression signatures should be done. These studies should not only focus on the prognostic significance of these measurements, but also on characterizing the changes in the level of the particular CSC phenotype before, during and after therapy as well as its Specific targeting of these cells (perhaps after primary therapy) may result in their eradication and thus prevent disease recurrence.
